These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34758679)

  • 1. Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics.
    Barrera-Chimal J; Kolkhof P; Lima-Posada I; Joachim A; Rossignol P; Jaisser F
    Expert Opin Investig Drugs; 2021 Nov; 30(11):1141-1157. PubMed ID: 34758679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
    Kintscher U
    Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Kintscher U; Bakris GL; Kolkhof P
    Br J Pharmacol; 2022 Jul; 179(13):3220-3234. PubMed ID: 34811750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?
    Gregg LP; Navaneethan SD
    Nephrol Dial Transplant; 2023 May; 38(6):1355-1365. PubMed ID: 36264349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease.
    Lo KB; Rangaswami J; Vaduganathan M
    Nephrol Dial Transplant; 2023 Mar; 38(4):845-854. PubMed ID: 36472546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
    Agarwal R; Kolkhof P; Bakris G; Bauersachs J; Haller H; Wada T; Zannad F
    Eur Heart J; 2021 Jan; 42(2):152-161. PubMed ID: 33099609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
    Sueta D; Yamamoto E; Tsujita K
    Curr Hypertens Rep; 2020 Feb; 22(3):21. PubMed ID: 32114686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis.
    Jiang X; Zhang Z; Li C; Zhang S; Su Q; Yang S; Liu X; Hu Y; Pu X
    Front Pharmacol; 2022; 13():896947. PubMed ID: 35784710
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.
    Pitt B; Rossignol P
    Expert Opin Drug Saf; 2016 May; 15(5):659-65. PubMed ID: 26958701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
    Pei H; Wang W; Zhao D; Wang L; Su GH; Zhao Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0254. PubMed ID: 29668577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.
    Kolkhof P; Bärfacker L
    J Endocrinol; 2017 Jul; 234(1):T125-T140. PubMed ID: 28634268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease.
    Watson K; Kukin A; Wasik AK; Shulenberger CE
    J Cardiovasc Pharmacol; 2021 Jun; 77(6):685-698. PubMed ID: 34057158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.
    Georgianos PI; Agarwal R
    Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor.
    Clarisse D; Deng L; de Bosscher K; Lother A
    Br J Pharmacol; 2022 Jul; 179(13):3235-3249. PubMed ID: 34698367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension.
    Pitt B; Jaisser F; Bakris G
    Expert Opin Investig Drugs; 2021 Oct; 30(10):1017-1023. PubMed ID: 34595995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsteroidal antagonists of the mineralocorticoid receptor.
    Kolkhof P; Nowack C; Eitner F
    Curr Opin Nephrol Hypertens; 2015 Sep; 24(5):417-24. PubMed ID: 26083526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.